Let me start by out­lin­ing a few things we’re not do­ing.

We’re not an­oth­er ag­gre­ga­tion ma­chine. There are plen­ty of places that will give you a quick and ster­ile snap­shot of the bio­phar­ma R&D world. And that’s not us.

We’re not the AP or any oth­er wire ser­vice. There’s al­ready an AP, Reuters, Bloomberg, and they do a fine job. That job is cov­ered.

We’re not stock pick­ers. Frankly, we wouldn’t know where to be­gin.

Many of you may know Pub­lish­er Ar­salan Arif and I from an ear­li­er com­pa­ny we worked at.

We’re not that com­pa­ny, ei­ther.

Fi­nal days as EIC @Fierce­Biotech. Jump­ing head first in­to @endpts as biotech writer/ed­i­tor/part­ner with @AKAarsalan.https://t.co/oAx­CC8C9W3

— John Car­roll (@John­Cendpts) June 9, 2016

So what are we?

We’re a deeply ex­pe­ri­enced team of own­er/ed­i­tors that has spent more than a decade learn­ing about glob­al drug de­vel­op­ment and dig­i­tal me­dia. We aim to put that ex­pe­ri­ence, and the con­tacts we’ve de­vel­oped in-per­son and on­line to work for you; an­a­lyz­ing in­dus­try news for in­dus­try pro­fes­sion­als, pro­vid­ing the da­ta and in­for­ma­tion need­ed to in­tel­li­gent­ly as­sess where the bio­phar­ma re­search in­dus­try is head­ed.

Yes, in ad­di­tion to break­ing sto­ries and plen­ty of en­tire­ly orig­i­nal con­tent, we will al­so source pubs around the globe in pur­suit of a big goal. But we will al­ways put the news in con­text. And we will al­ways cut to the chase. That’s our se­cret sauce. And it’s some­thing that can’t be cloned.

Over the past two years, Ar­salan has been de­vel­op­ing a new dig­i­tal news plat­form that em­ploys its own orig­i­nal ap­proach to high­light­ing the re­ports from around the globe that mat­ter most. That’s our Ear­ly Edi­tion, which he ham­mers away at dur­ing predawn hours. And he al­so has an en­ter­tain­ing/in­sight­ful col­lec­tion of links to the most sought-af­ter con­tent, ranked by Twit­ter pop­u­lar­i­ty.

You’ll find Ar­salan and I again in our main edi­tion at noon EST (pub time, Lon­don; Star­bucks time, San Fran­cis­co; the mid­night spe­cial in Shang­hai), pro­vid­ing an an­a­lyt­i­cal, da­ta dri­ven dai­ly re­port on the drug R&D world. I’ll spend my day fo­cused on in­ter­pret­ing the top news and pro­vid­ing a da­ta-dri­ven set of an­a­lyt­ics specif­i­cal­ly for bio­phar­ma pro­fes­sion­als. Go to endpts.com to catch the live stream, as I pur­sue a re­al-time con­ver­sa­tion with read­ers.

On­line fi­nan­cial news hasn’t just cre­at­ed a new out­let for me­dia. It’s fun­da­men­tal­ly de­mand­ed a new style that re­quires a lot of hands-on ex­pe­ri­ence.

That’s who we are.

It won’t all be 100% fin­ished. We’ll prob­a­bly nev­er be 100% done with any­thing. The busi­ness we’re in is chang­ing in ex­plo­sive ways. We’ll try to keep up, some­times we may try to lead.

If you’ve got ques­tions, drop me a line. The best way to un­der­stand is to read one of our re­ports.

We hope you sub­scribe and stay with us for this ride. We’ll work for it.

— John Car­roll   john@end­pointsnews.com